Treatment of acute otitis media in children. by Mar, C. Del et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/98489
 
 
 
Please be advised that this information was generated on 2018-07-08 and may be subject to
change.
n engl j med 364;18 nejm.org may 5, 2011 1775
c o r r e s p o n d e n c e
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Treatment of Acute Otitis Media in Children
To the Editor: Hoberman et al. (Jan. 13 issue)1 
report that antibiotics reduced “the time to reso-
lution of symptoms and reduced the overall symp-
tom burden” in children with acute otitis media, 
and they reject the null hypothesis on the basis of 
statistical benefit in three of four “primary” out-
comes. There is no explanation of, or correction 
for, the use of four primary outcomes. The Con-
solidated Standards of Reporting Trials recom-
mend against more than one primary outcome 
because of “the problems of interpretation asso-
ciated with multiplicity of analyses.”2
More troubling, the study protocol (available 
with the full text of the article at NEJM.org) 
identifies only one primary outcome, “time to 
resolution.” Of the remaining three outcomes 
called “primary” in the article, one is not in the 
protocol and two are explicitly identified as sec-
ondary.
On the basis of the study protocol, the pri-
mary outcome showed no benefit over placebo 
(P = 0.14), and the null hypothesis cannot be re-
jected. Moreover, diarrhea, the outcome identified 
in the protocol as the “primary safety outcome,” 
was associated with harm when the study drug 
was compared with placebo (P = 0.05). These re-
sults do not support the reported conclusions 
and appear to be an argument against antibiotic 
use in this population.
David H. Newman, M.D.
Mount Sinai School of Medicine 
New York, NY 
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To the Editor: We question the conclusions of 
Hoberman et al.; it is not unreasonable to con-
clude that acute otitis media is a disease most 
often treatable with time alone. Had a correction 
for multiple comparisons been applied, there 
would have been no statistically significant differ-
ences between the treatment and placebo groups. 
The low daily doses of acetaminophen adminis-
tered and the lack of topical analgesia may have 
biased the results against the null for symptom 
control as an outcome.1,2 Moreover, the visual 
inspection of the time-to-event curves (Fig. 2 of 
their article) indicates that the between-group dif-
ferences are not clinically meaningful. In addition, 
the study design does not provide a comparison 
of immediate treatment with a wait-and-see pre-
scription, an approach resulting in treatment of 
patients with acute otitis media that warrants an-
tibiotics while limiting antibiotic use overall.3 As 
such, the study design compared treatment with 
placebo when a beneficial, standard therapy (the 
wait-and-see prescription) might have more ap-
propriately served as an active control.4 Further 
comparative trials that include the wait-and-see 
approach are warranted before concluding that 
acute otitis media uniformly requires immediate 
antibiotic treatment.
this week’s letters
1775	 Treatment	of	Acute	Otitis	Media	in	Children
1779	 Dialysis	Catheters	and	Recombinant	Tissue	
	Plasminogen	Activator
1780	 Iniparib	in	Metastatic	Triple-Negative	Breast	Cancer
1781	 Glycerol	Kinase	Deficiency	in	Adult	Hypoglycemic	
Acidemia
The New England Journal of Medicine 
Downloaded from nejm.org at RADBOUD UNIVERSITEIT NIJMEGEN on March 6, 2017. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 364;18 nejm.org may 5, 20111776
David M. Spiro, M.D., M.P.H. 
Garth D. Meckler, M.D.
Oregon Health and Science University 
Portland, OR 
spirod@ohsu.edu
Donald H. Arnold, M.D., M.P.H.
Vanderbilt University Medical Center 
Nashville, TN
No potential conflict of interest relevant to this letter was re-
ported.
1. Hoberman A, Paradise JL, Reynolds EA, Urkin J. Efficacy of 
Auralgan for treating ear pain in children with acute otitis media. 
Arch Pediatr Adolesc Med 1997;151:675-8.
2. Bolt P, Barnett P, Babl FE, Sharwood LN. Topical lignocaine 
for pain relief in acute otitis media: results of a double-blind 
placebo-controlled randomized trial. Arch Dis Child 2008;93:40-4.
3. Little P, Gould C, Williamson I, Moore M, Warner G, Dun-
leavey J. Pragmatic randomised controlled trial of two prescrib-
ing strategies for childhood acute otitis media. BMJ 2001;322: 
336-42.
4. Spiro DM, Tay KY, Arnold DH, Dziura JD, Baker MD, Shapiro 
ED. Wait-and-see prescription for the treatment of acute otitis 
media: a randomized controlled trial. JAMA 2006;296:1235-41.
To the Editor: The article on acute otitis me-
dia by Hoberman et al. may overstate the bene-
fit of antimicrobial therapy for acute otitis media. 
Their study, which used validated scoring instru-
ments to quantify the time to resolution of symp-
toms of acute otitis media, produced results that 
were consistent with previous published data 
showing a marginal benefit from antibiotics for 
acute otitis media.1-4 These investigators also 
used subjective assessments of otoscopic signs to 
identify clinical failure, sometimes in otherwise 
asymptomatic patients. The authors did not dis-
close the proportion of patients with clinical fail-
ure at day 10 to 12 who had concurrent symp-
tom scores lower than the minimum score of 
3 required for entry into the study, but the article 
suggests the number exceeds 37%. The temporal 
disparity between resolution of symptoms and 
resolution of otoscopic signs of acute otitis media 
became the authors’ basis for describing a sig-
nificant benefit from antibiotics for acute otitis 
media. Remnant effusions may persist for days 
or weeks after an episode of acute otitis media 
has resolved, but they are not necessarily an indi-
cation for saturation of the population of patients 
who have acute otitis media with broad-spectrum 
antibiotics. One observer’s half-full middle-ear 
space might be another observer’s half-empty one.
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To the Editor: The two recent trials reported in 
the Journal by Hoberman et al. and Tähtinen et al.1 
and the accompanying editorial2 on antibiotics 
for acute otitis media in children overstate the 
impact of antibiotics in clinical practice. The ap-
parent effect size is greater than that reported in 
previous meta-analyses3,4 for two reasons. First, 
their end point combined symptoms with the 
proxy of the appearance of the tympanic mem-
brane (of doubtful clinical importance in a nor-
mally spontaneously remitting disease). Second, 
they used a much narrower definition of acute 
otitis media than is typical in practice (in this 
study, clinicians received special training, inclu-
sion criteria were stringent, and most patients 
were not eligible for enrollment because they were 
insufficiently ill). Sicker patients benefit more 
from any effective treatment. Some clinicians may 
think that they have freer license to prescribe anti-
biotics in children who are much less ill. Though 
the two trials showed statistically significant 
benefits associated with antibiotics, we think re-
stricted prescribing is still appropriate. Instead 
of simply deciding to treat all children, we should 
carefully balance harms and benefits, which gen-
erally means restricting antibiotics to the small 
group of younger, sicker children.4
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To the Editor: Tähtinen et al. evaluated a popu-
lation with a pneumococcal vaccination rate of 
2%, so the treatment effect of antibiotics in this 
population was probably overestimated. The over-
all number needed to treat was 3.8; however, the 
number needed to harm associated with adverse 
events was 6. It is difficult to establish whether 
these results apply to the population of vaccinat-
ed children in North America.
Amoxicillin–clavulanate, the drug used in the 
studies by Tähtinen et al. and Hoberman et al., 
is not considered to be first-line therapy for otitis 
media in children. A recent systematic review1 
concluded that amoxicillin is as good as other 
more expensive medications, and pooled results 
of seven studies showed a number needed to 
treat of 8 for amoxicillin–ampicillin. In the study 
by Hoberman et al., the number needed to treat 
was 17 for initial resolution of symptoms by day 
7 with amoxicillin–clavulanate and the number 
needed to harm was 6 for diarrhea and 3 for der-
matitis. Of interest, the two current studies showed 
a resolution rate with placebo of 55 to 74%.
Neither of these studies refutes the recommen-
dation of the American Academy of Pediatrics 
for a 48- to 72-hour wait-and-see-prescription for 
otitis media,2 nor do they prove that amoxicil-
lin–clavulanate is the best choice of antibiotic.
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To the Editor: Hoberman et al. and Tähtinen et 
al. suggest that amoxicillin–clavulanate is bene-
ficial in young children with acute otitis media, 
but their studies raise some questions. First, do 
they think that their results are applicable with 
a significant benefit in everyday practice? Most 
community episodes of acute otitis media are di-
agnosed by pediatricians who are not qualified 
otoscopists, and so there is a high risk of overdi-
agnosis.1 Without specific education and diag-
nostic validation, the universal use of antibiotics 
could do more harm than good. Second, why was 
amoxicillin–clavulanate used in both studies? 
Many guidelines suggest that amoxicillin is the 
first-choice antibiotic for acute otitis media,2,3 
and the use of broader-spectrum antimicrobial 
therapy for unselected cases is debatable.
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Dr. Hoberman and Colleagues Reply: New-
man and Shreves question our number of pri-
mary outcomes and our adherence to the study 
protocol. To measure symptomatic response ad-
equately, and with official sanction to use copri-
mary patient-reported outcomes,1 we settled on 
two — not four — primary outcomes: time to 
resolution of symptoms and symptom burden 
over time; each of these outcomes was measured 
in two ways. The four resulting measures were 
interrelated and were derived from a single set of 
symptom scores. We considered adjustment for 
multiple comparisons unnecessary; in general its 
application is debatable.2,3 Three of our four 
measures were described in the Primary Out-
come Measure section of the protocol’s Final 
Analysis Plan. The fourth was listed as second-
ary, but because it was closely related to one of 
the primary measures, we linked the two to form 
a single outcome. Diarrhea prompted discontin-
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uation of treatment by the parents of only 6 of 
144 children. We described the differences in 
symptom scores favoring antibiotic treatment as 
“modest”; more persuasive were the large differ-
ences in rates of clinical failure (16% among chil-
dren who received amoxicillin-clavulanate vs. 51% 
among children who received placebo by day 10 
to 12) as manifested by otoscopic evidence of 
continuing infection.
As Spiro and colleagues suggest, more aggres-
sive analgesic administration might have resulted 
in smaller between-group differences in sympto-
matic response; differences in clinical-failure 
rates, however, would have been unaffected, and 
the use of topical therapy would have compro-
mised otoscopic assessments. The cited trials of 
the approach involving the wait-and-see prescrip-
tion lacked blinding (of parents), validation of 
diagnoses, and objective assessment of the out-
come.4,5 In one of the trials,5 antibiotic prescrip-
tions were eventually filled for 53% of children 
younger than 2 years of age in the group as-
signed to the wait-and-see prescription, suggest-
ing that prompt treatment for those children 
might have been preferable.
It was not “remnant effusions,” as Grubb and 
Spaugh suggest, that we considered indicative of 
persisting middle-ear infection; rather, it was 
persistence of bulging of the tympanic mem-
brane in addition to otalgia or marked erythema 
of the membrane. With all data included, the 
numbers needed to harm for the occurrence of 
diarrhea and of diaper dermatitis were 10 and 6, 
respectively. The number needed to treat to pre-
vent clinical failure by day 10 to 12 was 3.
No data provide evidence to support the as-
sertion by Del Mar and colleagues that the ap-
pearance of the tympanic membrane is “of doubt-
ful clinical importance” in assessing outcome. 
Our stringent diagnostic criteria distinguished 
between children with and without acute otitis 
media, not between sicker and less sick sub-
groups of patients with the disease. We excluded 
no children for being “insufficiently ill.” Chil-
dren who presented with low symptom scores 
were excluded only because symptomatic response 
was a study outcome; all such children had bulg-
ing tympanic membranes.
In response to Crocco and to Principi and 
colleagues: we chose amoxicillin-clavulanate for 
our proof-of-concept study as the most effective 
antimicrobial agent available. The use of amoxi-
cillin may or may not have led to similar results; 
it remains our preferred first-line antimicrobial 
agent.
Alejandro Hoberman, M.D. 
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University of Pittsburgh 
Pittsburgh, PA 
hoberman@chp.edu
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. Guidance for industry — patient-reported outcome measures: 
use in medical product development to support labeling claims. 
Rockville, MD: Food and Drug Administration, Center for Drug 
Evaluation and Research, Center for Biologics Evaluation and 
Research, Center for Devices and Radiological Health, 2009. 
(http://www.fda.gov/downloads/Drugs/GuidanceCompliance 
RegulatoryInformation/Guidances/UCM193282.pdf.)
2. Cook RJ, Farewell VT. Multiplicity in the design and analysis 
of clinical trials. J R Stat Soc A 1996;159:93-110.
3. Perneger TV. What’s wrong with Bonferroni adjustments. 
BMJ 1998;316:1236-8.
4. Little P, Gould C, Williamson I, Moore M, Warner G, Dun-
leavey J. Pragmatic randomized controlled trial of two prescrib-
ing strategies for childhood acute otitis media. BMJ 2001;322: 
336-42.
5. Spiro DM, Tay KY, Arnold DH, Dziura JD, Baker MD, Shapiro 
ED. Wait-and-see prescription for the treatment of acute otitis 
media: a randomized controlled trial. JAMA 2006;296:1235-41.
Drs. Ruohola and Tähtinen Reply: We appre-
ciate the comments about our study and that of 
Hoberman et al. The two studies were independent 
of each other, and neither aimed to evaluate the 
optimal duration of treatment, dose of medica-
tion, or antimicrobial agent for acute otitis me-
dia. Also, the studies did not evaluate the wait-
and-see prescription. Amoxicillin–clavulanate was 
chosen to avoid underestimation of the treatment 
effect because of nonoptimal antimicrobial cov-
erage.
Our inclusion criteria were criticized for being 
stringent. No child was excluded for being in-
sufficiently ill, and only three children were ex-
cluded because of severe symptoms. Previously, 
we found that the children who were included 
and the children who were excluded had equal 
symptoms.1 Other investigators have found that 
pneumococcal vaccination causes only minor 
changes in the incidence and bacterial cause of 
acute otitis media.2 We used a stringent diagnos-
tic definition because we saw no rationale to 
study the efficacy of antimicrobial treatment in 
children who do not have true acute otitis media 
but rather only a red eardrum or clear fluid in 
the middle ear. Overdiagnosis is also our major 
concern.
Our primary outcome was integrated into the 
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diagnostic criteria. As Figure 4 of our article 
showed, acute otitis media is not always sponta-
neously remitting: otoscopic signs had not im-
proved at all or had deteriorated by the end-of-
treatment visit in 38% of placebo recipients. Even 
according to an alternative definition of treat-
ment failure, solely based on symptoms, antimi-
crobial treatment was beneficial. Our component 
of symptomatic failure was based on parental 
assessment of the child’s overall condition, be-
cause no symptom is specific to acute otitis me-
dia and the spectrum of symptoms varies among 
children and also among days in one child. Our 
holistic approach, easily applicable in clinical 
practice, did not measure any individual symp-
tom; rather, it measured all symptoms simulta-
neously, including adverse events. Thus, the com-
parison of the number needed to treat and the 
number needed to harm does not provide balance 
because, in our study, the clinical effects of harms 
are included in the number needed to treat.
We share the concern about the liberal use of 
antimicrobial agents. We agree that sicker patients 
benefit more from treatment, and this is what 
our study showed — “sicker” patients were those 
with bulging eardrums. If antimicrobial treat-
ment were restricted only to those patients, we 
would expect the use of antimicrobials to be 
decreased.
We acknowledge the diagnostic challenges and 
are aware that more education, as well as new 
technology, is urgently needed. However, we 
think that basing guidelines on the acceptance 
of the poor quality of diagnostics is not justified 
because they would lead to the withholding of 
treatment from children with true acute otitis 
media.
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Dialysis Catheters and Recombinant Tissue Plasminogen Activator
To the Editor: Hemmelgarn et al. (Jan. 27 is-
sue)1 evaluated prophylactic recombinant tissue 
plasminogen activator (rt-PA) for preventing di-
alysis catheter malfunction. I have a few caveats 
regarding their interpretation of the results.
The authors used a surrogate outcome (blood 
flow during dialysis) to define catheter malfunc-
tion. A more clinically meaningful end point, 
many would think, is the need for catheter re-
moval. Among those catheters in the heparin 
group in which malfunction developed, 50% re-
quired rt-PA instillation, but only 7.5% required 
removal because of malfunction (see Table 5 in 
the Supplementary Appendix, available with the 
full text of the article at NEJM.org). In other 
words, rt-PA instillation usually restored catheter 
patency. Rather than instilling rt-PA weekly, it 
might be more cost-effective to use heparin locks 
alone and reserve rt-PA instillation for catheters 
in which malfunction develops.
The authors observed less catheter-related bac-
teremia in the rt-PA group, which they attributed 
to prevention of bacterial biofilm. They enrolled 
only patients with incident-dialysis catheters. It is 
unknown whether rt-PA prevents catheter-related 
bacteremia in prevalent-dialysis catheters, which 
already have an established biofilm. Antimicro-
bial locking solutions, which reduce the inci-
dence of catheter-related bacteremia in patients 
with catheters for both incident and prevalent 
dialysis,2 may be preferred to prophylactic rt-PA 
instillation.
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The Authors Reply: We agree with Allon that 
rt-PA has been shown to be an effective strategy 
to treat catheter malfunction. As we found in our 
study, rt-PA as prophylaxis can reduce the risk of 
catheter malfunction and the requirement for 
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